2005

India admitted into Bush aid programme in same week that Indian parliament dismantles hope of future generic ARVs

18 April 2005. Related: Treatment access.

500mg saquinavir (Invirase) approved in Europe

18 April 2005. Related: Antiretrovirals.

Roche discontinue ddC and Fortovase

18 April 2005. Related: Antiretrovirals.

Needle-free injections for T-20 in US

18 April 2005. Related: Antiretrovirals.

Pegasys approved for HIV/hepatitis C coinfection in Europe and US

18 April 2005. Related: Hepatitis coinfection.

Pegasys approved in Europea for the treatment of chronic hepatitis B

18 April 2005. Related: Hepatitis coinfection.

Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries

18 April 2005. Related: On the web.

HIV inSite – new online resources

18 April 2005. Related: On the web.

PRN Notebook – December 2004

18 April 2005. Related: On the web.

Bulletin of Experimental Treatments for AIDS

18 April 2005. Related: On the web.

Volume 6 Number 4 April 2005 PDF

1 April 2005. Related: PDFs.

Volume 6 Number 2/3 February/March 2005

29 March 2005. Related: Editorial.

Important new pharmacokinetic data demonstrating that atazanavir sulfate (Reyataz) combined with ritonavir (Norvir) and proton pump inhibitors should not be coadministered

29 March 2005. Related: Treatment alerts.

7th International Congress on Drug Therapy in HIV Infection (ICDTHI), 14-18 November 2004, Glasgow

29 March 2005. Related: Conference reports.

Nandrolone decanoate combats HIV-related weight loss: results from three randomised studies

29 March 2005. Related: Conference reports, Coinfections and complications.

Atazanavir boosts intracellular saquinavir levels: data on important new dual-boosted regimen

29 March 2005. Related: Conference reports, Antiretrovirals, PK and drug interactions.

Marked variability in plasma atazanavir levels: importance of ritonavir boosting and TDM

29 March 2005. Related: Conference reports, Antiretrovirals.

Effective switching to atazanavir/ritonavir in clinical practice

29 March 2005. Related: Conference reports, Antiretrovirals.

Ritonavir boosting may not overcome interaction between atazanavir and nevirapine

29 March 2005. Related: Conference reports, Antiretrovirals.

Nevirapine associated adverse events in a cohort of pregnant women

29 March 2005. Related: Conference reports, Pregnancy.

Higher nevirapine doses for children leads to better outcome

29 March 2005. Related: Conference reports, Paediatric care.

TDM in Ugandan study highlights importance of refridgerated ritonavir

29 March 2005. Related: Conference reports, Antiretrovirals.

Responses to TB treatment in HIV positive and HIV negative patients in the UK

29 March 2005. Related: Conference reports, TB coinfection.

800mg efavirenz may not be needed with rifampicin-based TB regimens, especially in African patients

29 March 2005. Related: Conference reports, TB coinfection.

EuroSIDA shows HIV-HCV coinfected patients more likely to stop HAART because of side effects

29 March 2005. Related: Conference reports, Side effects.

Lower d4T dose maintains virologic suppression and CD4 increases

29 March 2005. Related: Conference reports, Antiretrovirals.

Community advocates meet with Indian generic companies: 2nd World CAB meeting

29 March 2005. Related: Treatment access.

AIDS activists concerned over drug prices post-patent

29 March 2005. Related: Treatment access.

India’s choice: editorial from NY Times

29 March 2005. Related: Treatment access.

Ranbaxy files three generic ARVs with US FDA

29 March 2005. Related: Treatment access.

FDA approves generic AZT/3TC/NVP fixed dose combination

29 March 2005. Related: Treatment access.

Treatment Access Campaign (TAC) awarded punitive costs in case against Minister of Health

29 March 2005. Related: Treatment access.

GSK grants license to Cipla in South Africa

29 March 2005. Related: Treatment access.

Widespread adoption of post exposure prophylaxis (PEP) recommended in US

29 March 2005. Related: Antiretrovirals.

European Approval For Kivexa (abacavir/3TC)

29 March 2005. Related: Antiretrovirals.

500 mg saquinavir (Invirase) approved in US

29 March 2005. Related: Antiretrovirals.

Interactions between African herbal medicines and ARVs

29 March 2005. Related: PK and drug interactions.

Indinavir not recommended in pregnancy due to reduced pharmacokinetic levels

29 March 2005. Related: Antiretrovirals, Pregnancy.

Free illustrated HIV guide for GPs and other primary care workers

29 March 2005. Related: Other news.

ARV drug recycling project in UK

29 March 2005. Related: Other news.

First pharmacogenomic CYP450 test designed for clinic use

29 March 2005. Related: Other news.

Role of HIV drug resistance testing in antiretroviral drug development

29 March 2005. Related: On the web.

Medscape full-text articles and guidelines

29 March 2005. Related: On the web.

Volume 6 Number 2/3 February/March 2005 PDF

1 March 2005. Related: PDFs.

Volume 6 Number 1 December 2004/January 2005

31 January 2005. Related: Editorial.

Important new clinical data: potential early virologic failure associated with the combination antiretroviral regimen of tenofovir disoproxil fumarate, didanosine, and either efavirenz or nevirapine in HIV treatment-naive patients with high baseline viral loads

31 January 2005. Related: Treatment alerts.

6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (IWADRLH) 26-28 October 2004, Washington

31 January 2005. Related: Conference reports.

Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues abacavir and tenofovir

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Nucleosides reduce PPAR-gamma: a role for rosiglitazone without thymidine analogues?

31 January 2005. Related: Conference reports.

Potential for uridine to treat mitochondrial toxicity: still only in vitro data

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

25% patients take Kaletra on an empty stomach: dietary advice often missed at ‘centre of excellence’

31 January 2005. Related: Conference reports, Antiretrovirals.

rHGH reduces central fat accumulation in adolescent lipodystrophy

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Weight loss is associated with elevated PBMC proviral DNA levels

31 January 2005. Related: Conference reports, Basic science and immunology.

Coronary artery bypass graft is safe in HIV-positive patients but shows higher risk of longer term events

31 January 2005. Related: Conference reports, Other news.

Endothelial dysfunction similar in ARV-experienced and -naive patients

31 January 2005. Related: Conference reports, Side effects.

Pravastatin improves lipid profiles but not endothelial function

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Indinavir impairs endothelial function without insulin resistance

31 January 2005. Related: Conference reports, Antiretrovirals.

Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Improvement of lipids following switch to tenofovir

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

HCV coinfection linked to discontinuing ART due to toxicity

31 January 2005. Related: Conference reports, Hepatitis coinfection.

Restorative treatments for HIV-associated lipoatrophy

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Post navigation